Laboratory for Immunology and Transfusion Medicine, Haugesund Hospital, Norway.
Norwegian Directorate of Health, Oslo, Norway.
Transfus Apher Sci. 2022 Aug;61(4):103487. doi: 10.1016/j.transci.2022.103487. Epub 2022 Jun 11.
When the COVID-19 pandemic hit, blood transfusion services worldwide started collection of convalescent plasma as early as possible, as exemplified by the response in Norway. There were challenges related to donor selection, donor safety, testing for relevant antibodies and indications for and dosing of the convalescent plasma. As more knowledge became available, the product quality was more standardised. Multiple case reports, observational studies and some randomized studies were published during the pandemic, as well as laboratory studies reporting different approaches to antibody testing. The results were conflicting and the importance of convalescent plasma was disputed. Even though there has been strong international collaboration with involvement of many key organisations, we may better prepare for the next pandemic. An even stronger, more formalised collaboration between these organisations could provide more clear evidence of the importance of convalescent plasma, based on the principles of passive immunisation.
当 COVID-19 大流行来袭时，世界各地的输血服务机构都尽早开始采集恢复期血浆，挪威的应对措施就是一个例子。在供者选择、供者安全、相关抗体检测以及恢复期血浆的适应证和剂量等方面都存在挑战。随着更多知识的出现，产品质量更加标准化。在大流行期间发表了多篇病例报告、观察性研究和一些随机研究，以及报告不同抗体检测方法的实验室研究。结果相互矛盾，恢复期血浆的重要性也存在争议。尽管已经有许多关键组织的国际合作，但我们可能还需要为下一次大流行做好更充分的准备。这些组织之间更强大、更正式的合作可以基于被动免疫的原则，提供更明确的证据来证明恢复期血浆的重要性。
